Braveheart Bio director reports 10.23M indirect shares
Braveheart Bio, Inc. director Vineeta Agarwala reported initial ownership on a Form 3.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Braveheart Bio, Inc. director Vineeta Agarwala reported initial ownership on a Form 3. The filing shows 10,232,420 shares of Common Stock held indirectly through AH Bio Fund IV, L.P., which also acts as nominee for several affiliated funds. AH Equity Partners Bio IV, L.L.C. is the general partner of AH Bio Fund IV and has sole voting and dispositive power over these securities. Agarwala is a member of AH Equity Partners Bio IV but disclaims beneficial ownership of the securities held by AH Bio Fund IV, except to the extent of any pecuniary interest.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Common Stock F1, F2 | -- | -- | -- |
Footnotes (2)
- F1. The reported securities are held by AH Bio Fund IV, L.P. ("AH Bio Fund IV"), for itself and as nominee for AH Bio Fund IV-B, L.P., AH 2022 Annual Fund, L.P., AH 2022 Annual Fund-B, L.P., AH 2022 Annual Fund-QC, L.P. and CLF Partners III, LP. AH Equity Partners Bio IV, L.L.C. ("AH EP Bio IV") is the general partner of AH Bio Fund IV and has sole voting and dispositive power with regard to the securities held by AH Bio Fund IV for itself and as nominee. The managing members of AH EP Bio IV are Marc Andreessen and Ben Horowitz. Marc Andreessen and Ben Horowitz may be deemed to share voting and dispositive power with respect to the securities held by AH Bio Fund IV for itself and as nominee.
- F2. The Reporting Person serves as one of the members of AH EP Bio IV, but she disclaims the existence of a "group" (as that term is used in Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")), and disclaims beneficial ownership of the securities directly held by AH Bio Fund IV, and this report shall not be deemed an admission that she is the beneficial owner of the securities reported herein for purposes of Section 16 of the Exchange Act, or for any other purpose, except to the extent of her pecuniary interest therein, if any.
Key Figures
Key Terms
beneficial ownership regulatory
pecuniary interest financial
dispositive power financial
voting power financial
indirect ownership financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Braveheart Bio (BRVE) director Vineeta Agarwala report on this Form 3?
What is AH Equity Partners Bio IV, L.L.C.’s role in the BRVE holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.